Morgan Stanley (NYSE:MS) analyst Matthew Harrison maintained a Buy rating on Zentalis Pharmaceuticals on Wednesday, setting a price target of $50, which is approximately 27.98% above the present share price of $39.07.
Harrison expects Zentalis Pharmaceuticals to post earnings per share (EPS) of -$0.78 for the fourth quarter of 2020.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Zentalis Pharmaceuticals, with an average price target of $45.67.
The analysts price targets range from a high of $50 to a low of $43.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$27.38 million. The company's market cap is $1.56 billion.
According to TipRanks.com, Morgan Stanley analyst Matthew Harrison is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.0% and a 60.98% success rate.
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery (NASDAQ:DISCA) Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company's product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.